Nimodipine reduces the risk of poor outcome and delayed cerebral ischemia in patients suffering aneurysmal subarachnoid haemorrhage (SAH), but its mode of action is unknown. Its beneficial effect is assumed to be due its neuroprotective effects by reducing intracellular calcium and thereby cellular apoptosis, but higher concentrations might induce marked systemic hypotension, thereby inducing cerebral ischemia. Since several dosing regimes and routes of administration with inconclusive superiority exist and since the target site concentration of nimodipine - the unbound drug concentrations beyond the blood-brain barrier - is still not known, it is reasonable to measure nimodipine concentrations within the blood, cerebrospinal fluid (CSF) and interstitial brain tissue following oral, intra-venous and intra-arterial administration and correlate intra-arterial nimodipine administration to measures of cerebral metabolism and oxygenation. Therefore, the investigators propose to investigate in 30 patients suffering severe aneurysmal SAH and requiring cerebral microdialysis for cerebral neurochemical monitoring: * the ability of nimodipine to penetrate into the brain of neurointensive care patients by comparing exposure in brain, CSF and plasma, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial) and dosing intra-venously (0.5 - 2mg/h) * the impact of orally, intra-venously, and intra-arterially delivered nimodipine on cerebral metabolism, i.e. lactate/pyruvate ratio, pbtO2 and transcranial doppler flow velocities * the effect of oral and intra-venous nimodipine on systemic hemodynamic and cardiac parameters, using continuous Pulse Contour Cardiac Output (PiCCO) monitoring * the penetration properties of ethanol - as an excipient of nimodipine infusion - into the brain by comparing exposure in brain, CSF and plasma and quantifying the neuronal exposure to alcohol dependent on blood levels
Study Type
OBSERVATIONAL
Enrollment
30
If application of nimodipine is clinically indicated patients will be enrolled in the study protocol according to the inclusion and exclusion criteria. The clinically appropriate route of administration will be administered according to the recommended regimen of the study drug; i.e. within the first 10-14 days intra-venous infusion and thereafter oral administration. Intra-arterial infusion will be performed due to severe cerebral vasospasm with impending stroke.
Medical University of Vienna
Vienna, Austria
RECRUITINGcerebral nimodipine concentrations
Area under the concentration-time curve in brain, cerebrospinal fluid and serum, dependent on the route of administration (i.e. oral, intra-venous, and intra-arterial)
Time frame: during the intervention
cerebral ethanol concentrations
Area under the concentration-time curve and maximum concentrations in brain tissue, CSF and blood after intravenous administration
Time frame: during the intervention
cerebral lactate/pyruvate ratio (LPR)
determined by cerebral microdialysis
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
brain tissue oxygen tension (pbtO2)
determined by cerebral parenchymal probes
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
cardiac output
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
fluid responsiveness
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
extravascular lung water index
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
systemic vascular resistance index
measured by Pulse Contour Cardiac Output (PiCCO) monitoring
Time frame: during the intervention
transcranial doppler flow velocities
measured in the middle cerebral artery ipsilateral to the microdialysis probe
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
angiographic vasospasm
mild: vessel diameter from 60-99%, moderate: vessel diameter from 30-59%, severe: vessel diameter \<30% of the physiological lumen
Time frame: immediately after the intervention
cerebral perfusion pressure
measured continuously via intra-arterial and intracranial probes
Time frame: during the intervention for oral and intravenous administered nimodipine, 12 hours after the intervention for intra-arterial nimodipine administration
incidence of delayed ischemic strokes
ischemic strokes on CT scans
Time frame: 3-21 days following subarachnoid haemorrhage
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.